Universe Pharmaceuticals (UPC) Non-Current Debt (2024)

Universe Pharmaceuticals' (UPC) quarterly Non-Current Debt came in at $2.1 billion in Q3 2024, up 102788.46% quarter-over-quarter from $2.1 million in Q1 2024.

Universe Pharmaceuticals (UPC) Non-Current Debt (2024) Analysis & Trends

Universe Pharmaceuticals has disclosed Non-Current Debt across 1 years of filings, most recently posting $2.1 billion for Q3 2024.

  • Non-Current Debt for Q3 2024 came in at $2.1 billion, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $2.1 billion (changed N/A YoY), and the FY2024 annual result was $2.1 billion, changed N/A from the prior year.
  • Non-Current Debt came in at $2.1 billion for Q3 2024 at Universe Pharmaceuticals, up from $2.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $2.1 billion in Q3 2024 to a low of $2.1 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 14.02 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 9.05 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn -
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 3.92 Bn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 1.48 Bn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 569.60 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn -
10 Universe Pharmaceuticals - - - -

Historic Data

Download Data
DateValue
Sep 30, 2024 2.14 Bn
Sep 30, 2024 2.14 Bn
Mar 31, 2024 2.08 Mn
Mar 31, 2024 2.08 Mn